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able toxicity.escalation. A total of 734 CBCT scans were evaluated. Small, medium, and large plans
were used in 36%, 48%, and 16% of cases, respectively. The mean  standard devi-
ation rate of intrafraction filling at the start of treatment (ie, week 1) was
4.0  4.8 mL/min (range 0.1-19.4) and at end of radiation therapy (ie, week 5 or 6)
was 1.1  1.6 mL/min (range 0.01-7.5; PZ.002). The mean D98 (dose received by
98% volume) of the tumor boost and bladder as assessed on the post-treatment CBCT
scan was 97.07%  2.10% (range 89.0%-104%) and 99.97%  2.62% (range 96.4%-
112.0%). At a median follow-up period of 19 months (range 4-33), no muscle-invasive
recurrences had developed. Two patients experienced late toxicity (both grade 3
cystitis) at 5.3 months (now resolved) and 18 months after radiation therapy.
Conclusions: Image guided adaptive radiation therapy using intensity modulated radi-
ation therapy to deliver a simultaneous integrated tumor boost to 70 Gy is feasible,
with acceptable toxicity, and will be evaluated in a randomized trial.  2016 The Au-
thors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Radical radiation therapy (RT) is an alternative to cys-
tectomy in appropriately selected patients with localized
muscle-invasive bladder cancer as a part of a multimodality
strategy (1, 2). Traditionally, the whole bladder has been
treated as the target, even in the presence of unifocal dis-
ease, to a standard dose of 60 to 64 Gy in 1.8- to 2-Gy
fractions to minimize the risk of significant late urinary
toxicity (3-5). However, most local recurrences after RT
develop at the original bladder tumor site, suggesting this
dose insufficiently addresses occult disease in some
patients (6). A higher dose could improve local control;
however, safely achieving this has been limited by the
uncertainties in target coverage (7-10).
The “plan of the day” image guided adaptive RT strategy
using kilovoltage computed tomography (CT; cone beam
CT [CBCT]) has mitigated the need for large population-
based margins to capture the known bladder variability
during RT (9-12). Several institutions have reported
improved target coverage and normal tissue sparing with
this approach (13-17). It therefore offers opportunity for
dose escalation to >64 Gy.
Partial bladder RT focused on delivering the dose to the
tumor alone rather than to the whole organ would further
spare the normal tissues (12). In randomized control studies,
tumor-focused 3-dimensional conformal RT techniques have
demonstrated no compromise to local control compared with
whole bladder treatment (18, 19). These studies predated the
routine use of CBCTand failed to demonstrate improvement
in urinary toxicitywith partial bladder RT.One reason for this
might have been treatment to an empty bladder with an
isotropicmargin of 1.5 cm around the tumor, which increased
the proportion of normal bladder exposed to the high-dose
region (18-20). Tumor-focused treatment to a full bladder
can improve normal bladder sparing, but it is associated with
difficulties in filling reproducibility (21-24).
Recent studies with intensity modulated RT (IMRT)
using the “plan of the day” approach have shown thattumor-focused dose escalation to 68 Gy can achieve local
control with minimal additional toxicity (22, 25). No re-
ports have been published of dose escalation beyond 68 Gy.
Studies of a bladder brachytherapy boost, treating focally
up to a combined total physical dose of w70 Gy, have
provided evidence that external beam RT can be safely
escalated to greater than current levels (8, 26-28). We
report the first clinical experience of delivering a simulta-
neous integrated tumor boost, escalating the dose to 70 Gy
in 32 fractions to a partially filled bladder with radiographer
led plan of the day RT approach.
Methods and Materials
The patients were recruited prospectively to an institutional
clinical research and ethics committeeeapproved RT dose
escalation protocol (NCT01124682), conducted in accor-
dance with European Union guidelines for good clinical
practice. The primary study endpoint of the maximum
tolerated dose will be reported separately after maturation
of the follow-up data. In the present report, we describe the
technical aspects of delivery.
Patient eligibility and selection
All eligible patients had pathologic evidence of muscle-
invasive bladder cancer of any histologic subtype and were
suitable to receive daily radical RT for stage T2-T4aN0M0
disease. Those with multifocal invasive disease or carci-
noma in situ remote from the tumor were excluded.
Treatment
The patients were treated with initial transurethral resec-
tion of the bladder tumor. Those suitable received 3 to 4
cycles of neoadjuvant chemotherapy (gemcitabine with
cisplatin). At cystoscopy, patients with no history of
contrast medium sensitivity or active thyroid disease
Hafeez et al. International Journal of Radiation Oncology  Biology  Physics1024received subepithelial ethiodized oil (Lipiodol) injected
into the bladder wall (3-6 spots) to demarcate the
maximum extent of visible tumor or tumor bed (29). RT
was delivered with concomitant chemotherapy where
appropriate (5-fluorouracil and mitomycin or weekly
gemcitabine) (30, 31).
RT planning
After voiding, the patients drank 350 mL of water, 30 mi-
nutes after which a noncontrast-enhanced planning CT scan
was performed (CT30), with scanning at 2.5-mm intervals
from the fourth lumbar vertebrae to below the ischial tu-
berosities, 30 minutes after which a second planning CT
scan (CT60) was acquired. No bladder emptying or drink-
ing was permitted between the 2 scans.
The images were exported in Digital Imaging and
Communications in Medicine format to the treatment
planning system (Pinnacle, version 9.6, Philips Medical
Systems). The CT30 and CT60 scans were fused. The gross
tumor volume (GTV) was defined as the visible tumor (or
tumor bed) and was delineated using the position of Lip-
iodol (where available), diagnostic imaging studies, and the
surgical bladder map. It was as outlined the maximal extent
of tumor seen on the pretreatment imaging study. The
clinical target volume (CTV) was contoured to encompass
the GTV, whole bladder, and any areas of extravesical
spread.
The planning target volumes (PTVs) were produced by
application of variable margins to the specified structures to
create small, medium, and large PTVboost and PTVbladder.
To model patient-specific filling, the large PTVs were
informed by the magnitude of bladder filling between the
CT30 and CT60 scans (Table 1).
Three plans were produced (small, medium, and large)
using 5 static field IMRT plans, ensuring in accordance
with International Commission on Radiation Units and
Measurements 83 recommendation that the PTV D98 (doseTable 1 PTV expansion details
CT data set PTV
Laterally
CT30 PTVboost small 0.5
CT30 PTVboost medium 0.5
CT30 if CTV difference on
CT60 and CT30 <50 cm3
PTVboost large 0.75
CT60 if CTV difference on
CT60 and CT30 >50 cm3
PTVboost large 0.5
CT30 PTVbladder small 0.5
CT30 PTVbladder medium 0.5
CT30 if CTV difference on
CT60 and CT30 <50 cm3
PTVbladder large 0.75
CT60 if CTV difference on
CT60 and CT30 >50 cm3
PTVbladder large 0.5
The margins were informed by previous work (13, 15).received by 98% volume) achieve 90% (mandatory) to 95%
(optimal) of the prescription dose (32). The PTVbladder was
prescribed to 52 Gy in 32 fractions. The PTVboost pre-
scription dose was assigned as 64, 68, or 70 Gy.
The rectum (including the anus), other bowel (including
the small and large bowel as a single structure), and
femoral heads were contoured as solid structures by
defining their outer wall on the CT30 scan. Constraint was
also specified for the normal bladder outside the PTVboost
(to quantify normal bladder sparing). The dose constraints
(Table E1; available online at www.redjournal.org) were
derived from previous phase 3 studies (CHHIP and
BC2001) (8, 30, 33, 34). In circumstances in which small or
medium plans failed to meet mandatory normal tissue
constraints, consideration was given to treat at a lower dose
level, which allowed the constraints to be met or if this was
not possible at the standard dose (64 Gy).
RT delivery
Before set up, the patients were asked to void their
bladder and then to drink 350 mL of water. The pre-
treatment CBCT scan was acquired at 30 minutes and co-
registered with the reference image (CT30) using an
automated bone match.
Two adaptive plan of the dayetrained radiographers
selected the smallest PTV and corresponding plan that
provided appropriate coverage of the bladder and tumor
boost, with a 3-mm margin to account for intrafraction
filling. Soft tissue matching was permitted to optimize
bladder coverage and minimize normal tissue irradiation.
The details have been previously presented (15, 35). In the
event that no PTV covered the bladder, the patients were
removed from the couch. Necessary interventions consid-
ered before reimaging are outlined in Figure E1 (available
online at www.redjournal.org). Post-treatment CBCT scans
were performed and reviewed on a weekly basis to assess
intrafraction filling.Anteriorly Posteriorly Superiorly Inferiorly
GTV to PTVboost expansion (cm)
0.5 0.5 0.5 0.5
0.5 0.5 0.5 0.5
2.0 1.2 2.5 0.75
1.5 1.0 1.5 0.5
CTV to PTVbladder expansion (cm)
0.5 0.5 0.5 0.5
1.5 1.0 1.5 0.5
2.0 1.2 2.5 0.75
1.5 1.0 1.5 0.5
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The patientswere assessed at baseline, weekly duringRT, and
at 4 and 8 weeks after treatment completion. Data regarding
acute toxicity were prospectively collected using the Com-
mon Terminology Criteria for Adverse Events, version 3.0.
The patients were then followed up at 3-month intervals
for 18 months, 6-month interval for 3 years, and annually
thereafter. Late toxicity was scored at these time points
using the Radiation Therapy Oncology Group (RTOG) late
radiation morbidity scoring schema.
Local control was assessed initially at 3 months using
rigid cystoscopy. Repeat cystoscopy was performed every
3 months for 2 years and annually thereafter. CT scans of
the chest, abdomen, and pelvis were performed at 1 and
2 years after treatment, with chest radiographs performed at
the interval time points.
Statistical considerations and evaluation of RT
Recruitment to the PTVboost dose level of 68 Gy or 70 Gy
was determined using the time-to-event continual reas-
sessment method. After treatment, the CBCT images were
imported into the planning system (Pinnacle, version 9.6).
Off line, a radiation oncologist (S.H.) assessed all plan
selections. The time between the pretreatment and post-
treatment CBCT scans was used as a surrogate for the
on-line plan selection time.
The tumor boost (GTV), whole bladder (CTV), and
normal bladder (excluding the tumor boost) were contoured
by a single observer (S.H.) on each CBCT scan. If the GTV
was not visible on the CBCT scan, it was reconstructed by
creating a mesh structure from the planning CT scan and
propagating it to the CBCT scan with adaptation to the
corresponding anatomy. The isodoses were overlaid to
determine the D98% to the target. The cumulative dose
received during the course of RT was determined (sum-
mation of the dose per fraction), accepting uncertainties
compared with actual treatment (36-41).
The conformity index (CIRTOG) was used as a surrogate
for normal nonebladder tissue RT. The CIRTOG was defined
by the proportion of the volume within the reference
isodose (95% and 98%) line of the selected plan for treat-
ment delivery compared with the target on that day (42). A
value close to 1 represents high conformity and implies less
normal tissue irradiation.
Comparisons of the delivered and planned treatment were
made using nonparametric statistics (Wilcoxon signed ranked
and independent sample Kruskal-Wallis analysis), corrected
for multiple testing (Bonferroni adjustment). All analyses
were performed using SPSS, version 22 (IBM,Armonk,NY).
Results
From June 2012 to May 2014, 20 patients were recruited.
The median age was 73 years (range 50-90). All patientshad stage T2-T3N0M0 transitional cell carcinoma. The
patient characteristics are listed in Table E2 (available on-
line at www.redjournal.org).
RT planning
The mean  standard deviation GTV was 22.37  16.3 cm3
(range 3.2-65.6). The mean CTV at 30 minutes and 60 mi-
nutes was 173.4  129.9 cm3 (range 89.6-696.9) and
229.7  162.3 cm3 (range 110-844.5), respectively. The
mean bladder filling was 53.4  61.2 cm3 (range 1.9-
252.4). The CT60 scan was used to inform the large plan
for 6 patients. One patient (patient 19) was unable to hold
her urine for the CT30 scan because of pre-existing grade 3
urinary symptoms and underwent imaging at 20 minutes.
All patients’ treatment was planned to their allocated
PTVboost prescription dose. Low-dose mandatory bowel
constraints (medium plan) were exceeded in 2 patients
(patients 4 and 10) allocated to 70 Gy. However, no
reduction of the allocated PTVboost prescription dose was
undertaken because de-escalation would not have improved
this.
Two patients underwent repeat planning at their allo-
cated PTVboost dose after the start of RT. Patient 4
demonstrated a change in bladder shape and filling during
week 1. A repeat CT30 scan was performed, and the new
small and medium plan was used from fraction 7. Patient 9
demonstrated a change in rectal filling, and a large plan was
re-created (without repeat scanning) and used from
fraction 14.
A total of 18 patients completed treatment to 70 Gy. The
plan and treatment for 1 patient was to 68 Gy, and 1 patient
was treated to 30 fractions (estimated total dose of 65.6 Gy
PTVboost) because dose-limiting toxicity occurred before
dose escalation.
CBCT acquisition
A total of 734 CBCT scans were evaluated (638 before RT
and 96 after RT). Of the 638 pre-RT CBCT scans, 22 (3%)
identified a significant bladder shape change with no plan
deemed suitable for treatment delivery. This necessitated
intervention (eg, bladder voiding) before repeat CBCT
scanning to ensure target coverage for treatment was
possible with the pre-existing library of plans. The total
number of CBCT exposures for each patient is shown in
Figure E2 (available online at www.redjournal.org).
Plan selection
Treatment was delivered using small, medium, and large
plans for 36.1%, 47.8%, and 16.1% cases, respectively.
Individual on-line plan selections are presented in Figure 1.
The off-line plan sections demonstrated concordance with
the radiographer plan selection of 94% (598 of 638). A
small, medium, large, and no plan was chosen for 36.4%,
35
30
25
20
15
10
5
0
1 2 3 4 5 6 7 8 9 10 11
Patient
To
ta
l n
um
be
r 
of
 f
ra
ct
io
ns
12 13 14 15 16 17 18 19 20
large
medium
small
Fig. 1. On-line plan selection.
Hafeez et al. International Journal of Radiation Oncology  Biology  Physics102646.2%, 17.1%, and 0.3% of fractions, respectively. Of the
40 fractions that were nonconcordant, the on-line choice
was smaller than the off-line selection on 21 occasions and
larger than the off-line selection on 17 occasions. For 2
fractions, no plan was deemed suitable for treatment.Target volume evaluation
The individual daily variation in tumor boost and bladder
volume during the course of RT compared with treatment
planning is presented in Figure 2. The mean bladder vol-
ume at the start of treatment was 164.1  77.7 cm3 (range
80.3-364.37) and as assessed on the final fraction was
138.0  54.3 cm3 (range 60.2-249.1; PZ.057).
The mean time between the pre- and post-CBCT scan
was 12:51  2.0 minutes (range 9-18). The mean intra-
fraction filling during this time was 12.2  14.4 cm3
(range 5.6 to 97.3). A significant decrease was seen in
the individual intrafraction filling during the treatment
course. The mean intrafraction filling at the start of
treatment was 50.7  60.6 cm3 (range 1.9-252.4) and as
assessed toward the end of RTwas 14.3  21.8 cm3 (range
0.1-97.3; PZ.001). The mean rate of intrafraction filling
at the start of treatment (ie, week 1) was 4.0  4.8 mL/min
(range 0.1-19.4) and as assessed toward the end of RT (ie,
week 5 or 6) was 1.1  1.6 mL/min (range 0.01-7.5;
PZ.002).
The mean D98 of the tumor boost and bladder for each
on-line plan selection was 97.14%  2.83% (range 82.4%-
100.5%) and 100%  2.77% (range 77.0%-111.6%),
respectively. The individual cumulative dose delivered to
the target volume during the treatment course is shown in
Figure E3 (available online at www.redjournal.org). Intra-
fraction filling and nonconcordant plan selection did not
adversely effect on-target coverage (Table E3; available
online at www.redjournal.org).Normal tissue sparing
All patients met the predefined dose constraints for normal
bladder sparing at RT planning. The mean cumulative
normal bladder volume to 60 Gy and 65 Gy was
43.1%  14.9% (range 19.9%-76.9%) and 28.1%  12.3%
(range 11.7%-59.2%), respectively, for actual treatment
(Fig. 3).
Significant improvements in the other low-dose bowel
constraints were seen with summated plan assessment
compared with the initial medium plan (Fig. E4; available
online at www.redjournal.org). The mean percentage of
target volume receiving 45% and 50% of the prescribed
dose was 85.2  54.7 cm3 (range 14.7-243.3) and
58.6  38.1 cm3 (range 8.4-179.8) as evaluated on the
medium plan compared with 67.6  45.6 cm3 (range 4.2-
165.4; PZ.02) and 42.9  29.4 cm3 (range 1.6-122.3;
PZ.04) for actual treatment delivery, respectively.
The mean CIRTOG of the 95% and 98% reference isodose
of the selected plan for treatment delivery to the tumor as
seen on CBCTwas 5.0  2.2 (range 2.1-21.4) and 3.7  1.6
(range 1.5-16.5) and to the whole bladder was 3.5  1.0
(range 1.7-8.9) and 3.0  0.8 (range 1.5-7.0), respectively.
The mean CIRTOG for plan selection and individual patients
is listed in Table E4 and shown in Figure E5 (available
online at www.redjournal.org).
Toxicity and response outcomes
At a median follow-up of 19 months (range 4-33), 17 pa-
tients were alive and disease free. No muscle-invasive re-
currences developed within this cohort. Two patients
developed nonemuscle-invasive recurrence and 3 patients
died of metastatic bladder cancer.
This technique was well tolerated (Fig. E6; available
online at www.redjournal.org). No late grade 3
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the latest follow-up examination. Two patients experienced
late urinary toxicity (grade 3 cystitis) at 5.3 months (now
resolved) and at 18 months (grade 3 cystitis managed
medically at the last follow-up visit) after RT.Discussion
Successful partial bladder RT is dependent on the reliability
of tumor definition on both the planning CT and the CBCT
scans. This is subject to interobserver variation and can alsobe hampered after transurethral resection of the bladder
tumor and neoadjuvant chemotherapy (43). Radiopaque
markers inserted at cystoscopy can help inform target
delineation, particularly in these circumstances (25, 29, 44).
Seven patients had neither visible disease at planning
nor ethiodized oil inserted. GTV reconstruction by mesh
manipulation on the CBCT scans in these patients arguably
is open to systematic error. The initial GTV delineation at
planning as the maximal extent of tumor seen on the pre-
treatment imaging study should have offset this by erring
toward a worst-case scenario. Even with careful adjust-
ments, in the absence of visible macroscopic disease to
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in the GTV variation on the CBCT scans. Target coverage
of the tumor boost should therefore be interpreted within
this context.
The tumor boost position relative to the bladder wall
remains stable; therefore, it can be assumed that in most
circumstances if the selected PTVappropriately covered the
bladder, the boost would also be covered. This is reassur-
ingly reflected clinically by the absence of muscle-invasive
recurrence. Future tumor boost delineation ambiguity might
be overcome by the development of magnetic resonance
imaging-fused or guided approaches (45).
Although we achieved excellent target coverage and
maintain normal bladder and bowel constraints, the high
mean CI suggests scope to improve conformity of the
current adaptive strategy. One approach would be to have a
greater range of plans. Other groups have produced more
extensive libraries for plan of the day approaches. Murthy
et al (22) reported that of their library of 6 IMRT plans, the
largest was not used at all and their second largest was used
for <1% of treatments. The balance therefore between
creating an extensive library of plans must be considered
against the effect on resources and clinical usefulness.
These larger libraries have also been associated with
increased time for plan selection, which has implications
for intrafraction filling and potentially a greater risk of error
(22, 25).
Appropriate plan selection in a timely fashion from the
choice of 3 plans was reflected in both our high off-line
concordance rate (94%) and our target coverage evaluation
on the post-treatment CBCT scan. Even in circumstances of
nonconcordant plan selections, the instances of dosimetric
compromise in which the D98 was <90% to either the
bladder or boost was seen in only 0.03% of fractions. It
reflects previous work that nonconcordance among trained
individuals is a “close call” (15).An alternative adaptive solution would be the develop-
ment of on-line autosegmentation and deformable regis-
tration, allowing individualized RT plans to be created in
real time (37). Pilot work has demonstrated potential
dosimetric advantages compared with plan of the day so-
lutions (40).
Margin selection for intrafraction filling will be more
critical with increased conformity. Studies have shown that
post-RT CBCT scans reveal that 5.5% and 16.1% of frac-
tions will have bladder outside the selected plan when
smaller uniform margins are used (22, 46). Application of
anisotropic margins with larger superior and anterior ex-
pansions appears to best capture intrafraction filling (9, 13,
47-51). This is likely to have maintained the apparent
robustness of our library to both inter- and intrafraction
changes.
In some circumstances, intrafraction margin reduction
during the treatment course should be contemplated with
caution, because a significant reduction in the mean rate of
intrafraction filling occurs over time. This might be a
reflection of patients moderating hydration to manage their
urinary symptoms. Any future margin reduction would
require implementation of volumetric modulated arc ther-
apy, given the faster treatment delivery times compared
with static field IMRT (52).
A trend suggesting a reduction in bladder filling with
time was seen, but no significant differences in bladder
volume at the start of RT compared with at the final fraction
were seen. This is in contrast to the findings from Foroudi
et al (16), who showed an estimated 27% (P<.0001)
decrease in median volume at the end of treatment.
Decreasing bladder filling during the treatment course,
presumably as a result of deteriorating urinary symptoms,
increases the normal bladder tissue exposed to the high-
dose region and the development of urinary toxicity.
Bladder volume consistency was maintained during our
Volume 94  Number 5  2016 High-dose image guided adaptive RT for bladder cancer 1029treatment because the drinking protocol and image acqui-
sition time were actively managed. It also ensured that for
most patients their initial library of 3 plans remained
relevant.Conclusions
The absence of local muscle invasive recurrence and low
rates of late toxicity are encouraging and supports delivery
of a simultaneous integrated 70-Gy tumor boost to a
partially filled bladder. A library of 3 plans with the current
margins successfully covered the spectrum of individual
patient target volume change and maintained the normal
tissue constraints. Whether this treatment approach is
deliverable in other centers and translates into clinically
meaningful outcomes for patients will be evaluated in
an international randomized phase 2 trial (RAIDER;
A randomised phase II trial of adaptive image guided stan-
dard or dose escalated tumour boost radiotherapy in the
treatment of transitional cell carcinoma of the bladder) (53).References
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